Sense and the science of childhood immunization: Can we achieve more with less?

Vaccine

Volumn 24, Issue 42-43, 2006, Pages 6460-6467

  Obaro, Stephen K ^a   Ota, Martin O ^b  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cost reduction; Dose; Reduced antigen; Vaccine

Indexed keywords

ANTHRAX VACCINE; BACTERIAL POLYSACCHARIDE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; PHOSPHATE; PNEUMOCOCCUS VACCINE; POLYRIBOSYL RIBITOL PHOSPHATE; POLYSACCHARIDE VACCINE; RECOMBINANT HEPATITIS B VACCINE; SMALLPOX VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANTHRAX; ANTIBODY BLOOD LEVEL; CHILDHOOD DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; DIPHTHERIA; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; HEPATITIS B; HUMAN; IMMUNIZATION; INFLUENZA; MEDICAL ETHICS; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS INFECTION; TETANUS;

ANTIGENS; CHILD; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION; IMMUNOLOGIC MEMORY; VACCINES;

EID: 33749440205     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.06.051     Document Type: Review

References (73)

1. The World Health Report 2005: make every mother and child count. Annex Tables 3 and 4: 190. Geneva, World Health Organ; 2005.
2. Buckland B.C. The process of development challenge for a new vaccine. Nat Med Suppl (2005) S16-S19
3. Andre F.E. How the research-based industry approaches vaccine development and establishes priorities. Dev Biol (Basel) 110 (2002) 25-29
4. Lambert P.H., Liu M., and Siegrist C.A. Can successful vaccines teach us how to induce efficient protective immune responses?. Nat Med 11 4 Suppl (2005) S54-S62
5. Olin P., Hallander H.O., Gustafsson L., Reizenstein E., and Storsaeter J. How to make sense of pertussis immunogenicity data. Clin Infect Dis 33 Suppl 4 (2001) S288-S291
6. Long S.S., Welkon C.J., and Clark J.L. Widespread silent transmission of pertussis in families: antibody correlates of infection and symptomatology. J Infect Dis 161 (1990) 480-486
7. Lee G.M., Lebaron C., Murphy T.V., Lett S., Schauer S., and Lieu T.A. Pertussis in adolescents and adults: should we vaccinate?. Pediatrics 115 (2005) 1675-1684
8. Picker L.J., Treer J.R., Ferguson-Darnell B., Collins P.A., Buck D., and Terstappen L.W.M.M. Control of lymphocyte recirculation in man. I Differential regulation of the peripheral lymph node homing receptor l-selectin on T cells during the virgin to memory cell transition. J Immunol 150 (1993) 1105-1121
9. MacLennan I., Garcia de Vinuesa C., and Casamayor-Palleja M. B cell memory and the persistence of antibody responses. Philos Trans R Soc Lond Biol Sci 355 (2000) 345-360
10. Swain S.L. CD4 T-cell memory can persist in the absence of class II. Philos Trans R Soc London Biol Sci 29 (2000) 407-411
11. Hathcock K.S., and Hodes R.J. Role of the CD28-B7 costimulatory pathways in T cell-dependent B cell responses. Adv Immunol 62 (1996) 131-166
12. Pawelec G., Rehbein A., Haenel K., Merl A., and Adibzadeh M. Human T cell clones in long term culture as a model of immunosenescence. Immunol Rev 160 (1997) 31-42
13. Doherty P.C., Topham D.J., and Tripp R. Establishment and persistence of virus-specific CD4+ and CD8+ T cell memory. Immunol Rev 150 (1996) 23-44
14. Nossal G.J.V., Austin C.M., and Ada G.L. Antigens in immunity. VII. Analysis of immunological memory. Immunology 9 (1965) 333-348
15. el-Ad B., Roth Y., Winder A., Tochner Z., Lubin-Tennenbaum, Katz E., et al. The persistence of neutralizing antibodies after revaccination against smallpox. J Infect Dis 161 (1990) 446-448
16. Monath T.P. Yellow fever: an update. Lancet Infect Dis 1 (2001) 11-20
17. West D.J., and Calandra G.B. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 14 (1996) 1019-1027
18. Ivins B.E., Pitt M.L., Fellows P.F., Farchaus J.W., et al. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 16 (1998) 1141-1148
19. Pinschewer D.D., et al. Kinetics of protective antibodies are determined by the viral surface antigen. J Clin Invest 114 (2004) 988-993
20. Nicol M., et al. Heamophilus influenzae type b conjugate vaccine diluted ten-fold in diphtheria-tetanus-whole cell pertussis vaccine: a randomized trial. Pediatr Infect Dis J 21 (2002) 138-141
21. Cassidy W.M., et al. A randomized trial of alternative two and three-dose hepatitis B vaccination regimens in adolescents: antibody responses, safety, and immunologic memory. Pediatrics 107 (2001) 626-631
22. Ahman H., Kayhty H., Vuorela A., Leroy O., and Eskola J. Dose dependency of antibody response in infants and children to pneumococcal polysaccharides conjugated to tetanus toxoid. Vaccine 17 (1999) 2726-2732
23. Bosnak M., Dikici B., Bosnak V., and Haspolat K. Accelerated hepatitis B vaccination schedule in childhood. Pediatr Int 44 (2002) 663-665
24. Manz R.A., Hauser A.E., Heipe F., and Radbruch A. Maintenance of serum antibody levels. Annu Rev Immunol 23 (2005) 367-386
25. Ochsenbein A.F., Pinschewer D.D., Sierro S., Horvath E., Hengartner H., and Zinkernagel R.M. Protective long-term antibody memory by antigen-driven and T help-dependent differentiation of long-lived memory B cells to short-lived plasma cells independent of secondary lymphoid organs. Proc Natl Acad Sci USA 97 (2000) 13263-13268
26. Slifka M.K., Anita R., Whitmire J.K., and Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity 8 (1998) 363-372
27. Bernasconi N.L., Traggiai E., and Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298 (2002) 2199-2202
28. Campos M., and Godson D.L. The effectiveness and limitations of immune memory; understanding protective immune responses. Int J Parasitol 33 (2003) 655
29. Zinkernagel R.M. On differences between immunity and immunological memory. Curr Opin Immunol 12 (2002) 523-536
30. Anderson P., Ingram D.L., Pinchero M.E., and Peter G. A high degree of natural immunologic priming to the capsular polysaccharide may not prevent Haemophilus influenzae type b meningitis. Pediatr Infect Dis J 19 (2000) 589
31. McVernon J., Johnson P.D., Pollard A.J., Slack M.P., and Moxon E.R. Immunologic memory in Haemophilus influenzae type b conjugate vaccine failure. Arch Dis Child 88 (2003) 379
32. Frey S.E., Couch R.B., Tacket C.O., et al. National Institute of Allergy and Infectious Diseases Smallpox Vaccine Study Group. Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med 346 (2002) 1265-1274
33. Kenney R.T., Frech S.A., Muenz L.R., Villar C.P., and Glenn G.M. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 351 (2004) 2295-2301
34. Gray B.M., Converse III G.M., and Dillon Jr. H.C. Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life. J Infect Dis 142 (1980) 923-933
35. Gold R., Lepow M.L., Goldschneider I., Draper T.F., and Gotschlich E.C. Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. J Infect Dis 140 (1979) 690-697
36. MMWR 2004; 53: March 2 Updated recommendations on the use of pneumococcal conjugate vaccine; suspension of recommendation for third and fourth dose.
37. Centers for Disease Control Prevention, Updated recommendations on the use of pneumococcal conjugate vaccine in a setting of vaccine shortage-Advisory Committee on Immunization Practices, JAMA 2002; 287:833-834.
38. Cutts F.T., Zaman S.M., Enwere G., et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 365 (2005) 1139-1146
39. Barzilay E.J., O'brien K.L., Kwok Y.S., et al. Could a single dose of pneumococcal conjugate vaccine in children be effective? Modeling the optimal age of vaccination. Vaccine 13 (2006) 904-913
40. Obaro S.K., Huo Z., Banya W.A., Henderson D.C., Monteil M.A., Leach A., et al. A glycoprotein pneumococcal conjugate vaccine primes for antibody responses to a pneumococcal polysaccharide vaccine in Gambian children. Pediatr Infect Dis J 12 (1997) 1135-1140
41. Klugman K.P., Madhi S.A., Huebner R.E., Kohberger R., Mbelle N., Pierce N., and Vaccine Trialists Group. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 349 (2003) 1341-1348
42. Kayhty H., Ahman H., Eriksson K., Sorberg M., and Nilsson L. Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age. Pediatr Infect Dis J 24 (2005) 108-114
43. Mulholland K., Hilton S., Adegbola R., et al. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine for prevention of pneumonia and meningitis in Gambian infants. Lancet 349 (1997) 1191-1197
44. Adegbola R.A., Secka O., Lahai G., et al. Elimination of Haemophilus influenzae type b disease from The Gambia after the introduction of routine immunization with an Hib conjugate vaccine. Lancet 366 (2005) 144-150
45. Trotter C.L., Ramsay M.E., and Slack M.P. Rising incidence of Haemophilus influenzae type b disease in England and Wales indicates a need for a second catch-up vaccination campaign. Commun Dis Public Health 6 (2003) 55-58
46. Whittle H.C., Aaby P., Samb B., Jensen H., Bennett J., and Simondon F. Effect of subclinical infection on maintaining immunity against measles in vaccinated children in West Africa. Lancet 353 (1999) 98-102
47. Brinsmead R., Hill S., and Walker D. Are economic evaluations of vaccines useful to decision-makers? Case study of Haemophilus influenzae type b vaccines. Pediatr Infect Dis J 23 (2004) 32-37
48. Granoff D.M., Rathore M.H., Holmes S.J., Granoff P.D., and Lucas A.H. Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines. Vaccine 11 Suppl 1 (1993) S46-S51
49. Guimaraes T., Cereda R.F., Bianchin P.J., Nagao A.T., Sampaio M.C., and Mendonca J.S. Antibody response to Haemophilus influenzae type b tetanus conjugate vaccine with two doses given at 3 and 5 months of age. Int J infect Dis 6 (2002) 113-117
50. Huebner R.E., Nicol M., Mothupi R., et al. Dose response of CRM197 and tetanus toxoid-conjugated Haemophilus influenzae type b vaccines. Vaccine 23 (2004) 802-806
51. Nicol M., Huebner R., Mothupi R., Kayhty H., Mbelle N., and Khomo E. Haemophilus influenzae type b conjugate vaccine diluted ten-fold in diphtheria-tetanus-whole cell pertussis vaccine: a randomized trial. Pediatr Infect Dis J 21 (2002) 138-141
52. Lagos R., Valenzuela M.T., Levine O.S., et al. Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunogenicity of fractional-dose and two-dose regimens. Lancet 351 (1998) 1472-1476
53. Campbell J.D., Lagos R., Levine M.M., and Losonsky G.A. Standard and alternative regimens of Haemophilus influenzae type b conjugate vaccine (polyribosylribitol phosphate-tetanus toxoid conjugate vaccine) elicit comparable antibody avidities in infants. Pediatr Infect Dis J 9 (2002) 822-826
54. Levine O.S., Granoff D.M., Lagos R., Fritzell B., and Levine M.M. Factors associated with superior antibody responses to a single dose of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine administered to Chilean infants at 2 months of age. Vaccine 3 (1997) 325-328
55. Kauppi M., Eskola J., and Käyhty H. Anti-capsular polysaccharide antibody concentrations in saliva after immunization with Haemophilus influenzae type b conjugate vaccines. Pediatr Infect Dis J 14 (1995) 286-294
56. Kao J.H., and Chen D.S. Global control of hepatitis B virus infection. Lancet Infect Dis 2 7 (2002) 395-403
57. Mast E., Mahoney F., Kane M., and Margolis H. Hepatitis B vaccine. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines. 4th ed. (2004), Saunders Company, Philadelphia, PA 299-337
58. Kane M. Global programme for control of hepatitis B infection. Vaccine 13 Suppl 1 (1995) 47-49
59. Redfield R.R., Innis B.L., Scott R.M., et al. Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine. JAMA 254 (1985) 3203-3206
60. Bryan J.P., Sjogren M.H., Perine P.L., and Legters L.J. Low-dose intradermal and intramuscular vaccination against hepatitis B. Clin Infect Dis 14 (1992) 679-707
61. Cassidy W.M., Watson B., Ioli V.A., Williams K., Bird S., and West D.J. A randomized trial of alternative two- and three-dose hepatitis B vaccination regimens in adolescents: antibody responses, safety, and immunologic memory. Pediatrics 107 (2001) 626-631
62. Jilg W., Schmidt M., and Deinhardt F. immune response to hepatitis B revaccination. J Med Virol 24 (1988) 377-384
63. Grubeck-Loebenstein B., and Wick G. Proceedings of a symposium on immunosenescence: a major cause of disease in the elderly from molecules to patients (summary). Exp. Gerontol. 34 3 (1999) 407-411
64. Cooper C.L., Davis H.L., Morris M.L., Efler S.M., Adhami M.A., Krieg A.M., et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 24 6 (2004) 693-701
65. Mconnet I., Koenig S., Speiser D., et al. CpG are efficient adjuvants for specific CTL induction against against tumour antigen-derived peptide. Immunology 168 (2002) 1212-1218
66. Verthelyi D., Kenney R.T., Seder R.A., et al. CpG oligodeoxynucleotides as vaccine adjuvants in primates. J Immunol 168 (2002) 1659-1663
67. Greenwood B. Maternal immunisation in developing countries. Vaccine 21 (2003) 3436-3441
68. Santosham M., Englund J.A., McInnes P., et al. Safety and antibody persistence following Haemophilus influenzae type b conjugate or pneumococcal polysaccharide vaccines given before pregnancy in women of childbearing age and their infants. Pediatr Infect Dis J 10 (2001) 931-940
69. Siegrist C.A. Neonatal and early life vaccinology. Vaccine 19 (2001) 3331-3346
70. Elguero E., Simondon K.B., Vaugelade J., Marra A., and Simondon F. Non-specific effects of vaccination on child survival? A prospective study in Senegal. Trop Med Int Health 10 (2005) 956-960
71. Ota M.O., Vekemans J., Schlegel-Haueter S.E., et al. Influence of Mycobacterium bovis bacillus Calmette-Guerin on antibody and cytokine responses to human neonatal vaccination. J Immunol 168 (2002) 919-925
72. Meyerhoff A.S., Weniger B.G., and Jacobs R.J. Economic value to parents of reducing pain and emotional distress of childhood vaccine injections. Pediat Infect Dis J 20 Suppl 11 (2001) S57-S62
73. Decker M. Principles of pediatric combination vaccines and practical issues related to use in clinical practice. Pediatr Infect Dis 20 (2001) S10-S18